Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Dec 12;64(6):2402055.
doi: 10.1183/13993003.02055-2024. Print 2024 Dec.

Reply to: Is there a kindling effect in COPD exacerbations?

David M G Halpin  1   2 , Heath Heatley  3 , David Price  2   3   4
Affiliations
Comment

Reply to: Is there a kindling effect in COPD exacerbations?

David M G Halpin et al. Eur Respir J. .

Abstract

Real world studies have shown that over half of the patients having an exacerbation will not have one in the next year, suggesting that the majority of patients are not subject to a “kindling effect” https://bit.ly/3O016tT

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D.M.G. Halpin has received sponsorship to attend international meetings, and honoraria for lecturing, attending advisory boards and preparing educational materials from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Inogen, Meanrini, Novartis and Sanofi. H. Healey is an employee of the Observational and Pragmatic Research Institute. D. Price reports advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme and Thermo Fisher, consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc., Strategic North Limited, Synapse Research Management Partners SL, Talos Health Solutions, Theravance and WebMD Global LLC, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service, payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, payment for travel, accommodation and/or meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis and Thermo Fisher, stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, 74% ownership of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore), 5% shareholding in Timestamp which develops adherence monitoring technology, is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment, and was an expert witness for GlaxoSmithKline.

Comment on

References

    1. Halpin DMG, Heatley H, Skinner D, et al. . Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations. Eur Respir J 2024; 64: 2302240. doi:10.1183/13993003.02240-2023 - DOI - PMC - PubMed
    1. Agustí A, Celli BR, Criner GJ, et al. . Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J 2023; 61: 2300239. doi:10.1183/13993003.00239-2023 - DOI - PMC - PubMed
    1. Higham A, Beech A, Singh D. The relevance of eosinophils in chronic obstructive pulmonary disease: inflammation, microbiome and clinical outcomes. J Leukoc Biol 2024; 116: 927–946. doi:10.1093/jleuko/qiae153 - DOI - PubMed
    1. Mayhew D, Devos N, Lambert C, et al. . Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 2018; 73: 422–430. doi:10.1136/thoraxjnl-2017-210408 - DOI - PMC - PubMed
    1. Kardos P, Vogelmeier C, Worth H, et al. . A two-year evaluation of the ‘real life' impact of COPD on patients in Germany: the DACCORD observational study. Respir Med 2017; 124: 57–64. doi:10.1016/j.rmed.2017.02.007 - DOI - PubMed

LinkOut - more resources